Efficacy vs SYMBICORT TURBUHALER 400/12^* (an ICS/LABA)

Help patients breathe better today with TRELEGY, the #1 prescribed triple therapy for COPD^†

FULFIL, a non-US study, compared 24 weeks of once-daily TRELEGY with twice-daily ICS/LABA therapy. ¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

See results from IMPACT, a landmark trial of 10,000+ patients with a history of COPD exacerbations.

^†Based on IQVIA Patient Level Data as of November 2020.

Lung Function: FULFIL Health-Related Quality-of-life: FULFIL Exacerbation Rate: FULFIL Adverse Events: FULFIL

Lung Function: FULFIL
Health-Related Quality-of-life: FULFIL
Exacerbation Rate: FULFIL
Adverse Events: FULFIL

TRELEGY significantly improved lung function

In a 24-week, non-US study

Significant lung function improvement vs twice-daily SYMBICORT TURBUHALER 400/12* (an ICS/LABA)¹

Co-primary endpoint: change from baseline in trough FEV₁ at Week 24^1,4

*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

See FULFIL lung function data at 52 weeks (extension data)1,4

In an additional analysis (not adjusted for multiplicity): TRELEGY demonstrated a 179-mL improvement in lung function vs SYMBICORT TURBUHALER 400/12.*^1,4

LS mean change from baseline in trough FEV₁ at Week 52 was 126 mL for TRELEGY (n=183) and –53 mL for SYMBICORT TURBUHALER 400/12^* (n=171)^1,4

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3
FULFIL study description1,4

Design: A 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter study evaluating the effect of TRELEGY 100/62.5/25 mcg administered once daily compared with SYMBICORT TURBUHALER 400/12^* mcg administered twice daily. Patients were eligible if they were symptomatic with a postbronchodilator FEV₁ <50% predicted normal or an FEV₁ <80% predicted normal and a documented history of ≥2 moderate exacerbations or 1 severe (hospitalized) exacerbation in the previous 12 months. A subset of 430 patients continued on blinded treatment through an extension phase for up to 52 weeks.

Patients: At screening, patients (N=1810, mean age: 63.9 years) with COPD had a mean postbronchodilator percent predicted FEV₁ of 45.3% and a mean postbronchodilator FEV₁/FVC ratio: 0.45. In the 12 months prior to screening, 35% of patients had no moderate to severe exacerbations. Patients were randomized to treatment following a 2-week run-in period on their current COPD treatment. Current medications included ICS + LABA (29%), ICS + LABA + LAMA (28%), LAMA + LABA (10%), LAMA (9%), and other (24%).

Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

TRELEGY significantly improved quality of life

In a 24-week non-US study, patients taking TRELEGY were more likely to show an improvement in quality of life at Week 24 vs SYMBICORT TURBUHALER 400/12,^* as measured by SGRQ.¹

SGRQ is a validated, respiratory disease-specific, patient-reported instrument that assesses symptoms, activities, and impact on daily life domains.⁵

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

In a 24-week, non-US study

TRELEGY significantly improved quality of life vs twice-daily SYMBICORT TURBUHALER 400/12^* (an ICS/LABA)¹

Co-primary endpoint: change from baseline in SGRQ total score at Week 24¹

Results reflect rounding.

*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

Supporting analysis: SGRQ responder rate^‡ at Week 24¹

Analysis was not adjusted for multiplicity.

^‡Responder rate is the percentage of patients with a response, defined as a decrease from baseline of 4 or more in SGRQ total score.¹

See FULFIL health-related quality-of-life data at 52 weeks (extension data)1

In an additional analysis (not adjusted for multiplicity), TRELEGY (n=182) demonstrated an improvement from baseline in SGRQ total score of –4.6 units compared with –1.9 units for SYMBICORT TURBUHALER 400/12^* (n=174) at Week 52; difference –2.7 (95% CI: –5.5, 0.2).¹

The SGRQ responder rate at Week 52 was greater for TRELEGY (44%, 91/209) compared with SYMBICORT TURBUHALER 400/12^* (33%, 73/219) with an odds ratio of 1.5 (95% CI: 1.01, 2.24)¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3
FULFIL study description1,4

Design: A 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter study evaluating the effect of TRELEGY 100/62.5/25 mcg administered once daily compared with SYMBICORT TURBUHALER 400/12^* mcg administered twice daily. Patients were eligible if they were symptomatic with a postbronchodilator FEV₁ <50% predicted normal or an FEV₁ <80% predicted normal and a documented history of ≥2 moderate exacerbations or 1 severe (hospitalized) exacerbation in the previous 12 months. A subset of 430 patients continued blinded treatment through an extension phase for up to 52 weeks.

Patients: At screening, patients (N=1810, mean age: 63.9 years) with COPD had a mean postbronchodilator percent predicted FEV₁ of 45.3% and a mean postbronchodilator FEV₁/FVC ratio: 0.45. In the 12 months prior to screening, 35% of patients had no moderate to severe exacerbations. Patients were randomized to treatment following a 2-week run-in period on their current COPD treatment. Current medications included ICS + LABA (29%), ICS + LABA + LAMA (28%), LAMA + LABA (10%), LAMA (9%), and other (24%).

Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

TRELEGY: exacerbation rate

Exacerbation rate vs twice-daily SYMBICORT TURBUHALER 400/12^*(an ICS/LABA)¹

In a 24-week, non-US study

Secondary endpoint: annual rate of moderate to severe exacerbations¹

Endpoint was not adjusted for multiplicity

This study included patients who had received triple therapy (ICS + LABA + LAMA) before entering and were stepped down to the comparator arm (ICS/LABA).¹

Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

FULFIL study description1,4

Design: A 24-week, randomized, double-blind, double-dummy, parallel-group, multicenter study evaluating the effect of TRELEGY 100/62.5/25 mcg administered once daily compared with SYMBICORT TURBUHALER 400/12^* mcg administered twice daily. Patients were eligible if they were symptomatic with a postbronchodilator FEV₁ <50% predicted normal or an FEV₁ <80% predicted normal and a documented history of ≥2 moderate exacerbations or 1 severe (hospitalized) exacerbation in the previous 12 months. A subset of 430 patients continued blinded treatment through an extension phase for up to 52 weeks.

Patients: At screening, patients (N=1810, mean age: 63.9 years) with COPD had a mean postbronchodilator percent predicted FEV₁ of 45.3% and a mean postbronchodilator FEV₁/FVC ratio: 0.45. In the 12 months prior to screening, 35% of patients had no moderate to severe exacerbations. Patients were randomized to treatment following a 2-week run-in period on their current COPD treatment. Current medications included ICS + LABA (29%), ICS + LABA + LAMA (28%), LAMA + LABA (10%), LAMA (9%), and other (24%).

Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.¹

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

Adverse events and additional safety information from the 24-week, non-US FULFIL trial

The most commonly reported adverse events with ≥2% incidence from the 24‑week FULFIL trial, a non-US study^1,4

	TRELEGY 100/62.5/25 (n=911) %	SYMBICORT TURBUHALER 400/12* (n=899) %
Nasopharyngitis	7	5
Headache	5	6
URTI	2	2
COPD^§	2	3
Back pain	2	2
Arthralgia	2	1
Pneumonia	2	<1
Pharyngitis	2	1

^*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.^2,3

^§Signs, symptoms, or progression of COPD are more severe than expected for the subject's condition.

Pneumonia incidence as reported from adverse events of special interest from the 24-week FULFIL trial, a non-US study¹

TRELEGY

100/62.5/25

SYMBICORT

TURBUHALER 400/12*

24 Weeks

(n=911)

2.2

(n=899)

0.8

52 Weeks
(treatment subgroup)

(n=210)

1.9

(n=220)

1.8

See helpful resources for your practice and your patients.

Explore resources

Review the studies of TRELEGY vs SYMBICORT + SPIRIVA.

See details

See adverse reactions in COPD, including long-term (52-week) data.

View data

Review a head-to-head trial of TRELEGY in adult patients with ASTHMA.

Learn more

INDICATIONS

IMPORTANT SAFETY INFORMATION

INDICATIONS & IMPORTANT SAFETY INFORMATION

INDICATIONS

COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Asthma: TRELEGY is for maintenance treatment of adults with asthma.

Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Asthma: TRELEGY is for maintenance treatment of adults with asthma.

Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

INDICATIONS

COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Asthma: TRELEGY is for maintenance treatment of adults with asthma.

Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TRELEGY is contraindicated in the following:

Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
Patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate (FF), umeclidinium (UMEC), vilanterol (VI), or any of the excipients.

WARNINGS AND PRECAUTIONS

Long-acting beta₂-adrenergic agonist (LABA) monotherapy for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, available data also suggest an increased risk of asthma-related hospitalization. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with inhaled corticosteroids (ICS), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. TRELEGY is not indicated for use in pediatric patients aged 17 years and younger.
TRELEGY should NOT be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.
TRELEGY is NOT a rescue medication and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta₂-agonist.
TRELEGY should not be used more often or at higher doses than recommended or with another LABA for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, like LABA.
Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing fluticasone furoate. Advise patients to rinse their mouths with water without swallowing after inhalation.
Lower respiratory tract infections, including pneumonia, have been reported following use of ICS, like fluticasone furoate. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD, as clinical features of pneumonia and exacerbations frequently overlap.
A more serious or even fatal course of chickenpox or measles may occur in susceptible patients using corticosteroids. ICS should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to TRELEGY.
Hypercorticism and adrenal suppression may occur with higher than the recommended dosage or at the regular dosage of ICS in susceptible individuals. If such changes occur, reduce the dose of TRELEGY slowly and consider other treatments for management of COPD or asthma symptoms.
Caution should be exercised when considering the coadministration of TRELEGY with ketoconazole and other known strong CYP3A4 inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid and cardiovascular adverse effects may occur.
If paradoxical bronchospasm occurs, discontinue TRELEGY and institute alternative therapy.
Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of TRELEGY. Discontinue TRELEGY if such reactions occur.
Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, TRELEGY may need to be discontinued. TRELEGY should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Decreases in bone mineral density have been observed with long‐term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care prior to initiating TRELEGY and periodically thereafter.
Glaucoma, increased intraocular pressure, and cataracts have been reported following the long‐term administration of ICS or inhaled anticholinergics. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use TRELEGY long term.
Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a healthcare provider immediately if signs or symptoms of acute narrow-angle glaucoma develop.
Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if signs or symptoms of urinary retention develop.
Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
Be alert to hypokalemia and hyperglycemia.
Orally inhaled corticosteroids may reduce growth velocity in children and adolescents.

ADVERSE REACTIONS: TRELEGY 100/62.5/25 MCG FOR COPD

In subjects with COPD, the most common adverse reactions (≥1% and more common than placebo + FF/VI) reported in two 12-week clinical trials with UMEC + FF/VI, the components of TRELEGY, (and placebo + FF/VI) were: headache, 4% (3%); back pain, 4% (2%); dysgeusia, 2% (<1%); diarrhea, 2% (<1%); cough, 1% (<1%); oropharyngeal pain, 1% (0%); and gastroenteritis, 1% (0%).
Additional adverse reactions (≥1% incidence) reported in subjects with COPD taking TRELEGY in a 52-week trial included upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, urinary tract infection, and dysphonia.

ADVERSE REACTIONS: TRELEGY FOR ASTHMA

In subjects with asthma, the most common adverse reactions (≥2% incidence with TRELEGY) reported in a 24-week to 52-week clinical trial with:
- TRELEGY 100/62.5/25 mcg (or FF/VI 100/25 mcg) were: pharyngitis/nasopharyngitis, 17% (16%); headache, 9% (7%); upper respiratory tract infection/viral upper respiratory tract infection, 5% (7%); respiratory tract infection/viral respiratory tract infection, 4% (4%); bronchitis, 4% (3%); influenza, 4% (3%); back pain, 3% (4%); sinusitis/acute sinusitis, 2% (3%); rhinitis, 2% (3%).
- TRELEGY 200/62.5/25 mcg (or FF/VI 200/25 mcg) were: pharyngitis/nasopharyngitis, 15% (16%); upper respiratory tract infection/viral upper respiratory tract infection, 7% (6%); headache, 5% (6%); bronchitis, 5% (5%); sinusitis/acute sinusitis, 3% (2%); respiratory tract infection/viral respiratory tract infection, 3% (2%); back pain, 2% (1%); urinary tract infection, 2% (<1%).

DRUG INTERACTIONS

TRELEGY should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because they may potentiate the effect of vilanterol on the cardiovascular system.
Use beta‐blockers with caution, as they not only block the pulmonary effect of beta‐agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD or asthma.
Use with caution in patients taking non–potassium-sparing diuretics, as ECG changes and/or hypokalemia associated with these diuretics may worsen with concomitant beta-agonists.
Avoid coadministration of TRELEGY with other anticholinergic-containing drugs, as this may lead to an increase in anticholinergic adverse effects.

USE IN SPECIFIC POPULATIONS

TRELEGY is not indicated for use in children and adolescents. The safety and efficacy in pediatric patients (aged 17 years and younger) have not been established.
Use TRELEGY with caution in patients with moderate or severe hepatic impairment, as fluticasone furoate systemic exposure may increase by up to 3-fold. Monitor for corticosteroid-related side effects.

Please see full Prescribing Information, including Patient Information, for TRELEGY.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TRELEGY is contraindicated in the following:

Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.

CONTRAINDICATIONS

TRELEGY is contraindicated in the following:

Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.

IMPORTANT SAFETY INFORMATION

${body_static_right}

Definitions

CI=confidence interval; COPD=chronic obstructive pulmonary disease; FEV₁=forced expiratory volume in 1 second; FF=fluticasone furoate; FULFIL=lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy; FVC=forced vital capacity; ICS=inhaled corticosteroid; IMPACT=InforMing the PAthway of COPD Treatment; LABA=long-acting beta₂-adrenergic agonist; LAMA=long-acting muscarinic antagonist; LS=least squares; MDI=metered-dose inhaler; OR=odds ratio; SGRQ=St. George's Respiratory Questionnaire; UMEC=umeclidinium; URTI=upper respiratory tract infection; UTI=urinary tract infection; VI=vilanterol.

References

Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438-446, Online Data Supplement.
SYMBICORT [US package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; July 2019.
SYMBICORT [UK package insert]. Luton, LU1, 3LU, UK; AstraZeneca UK Ltd; December 2018.
Data on file, GSK.
Jones PW, Quirk FW, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

TRELEGY ELLIPTA was developed in collaboration with

The shape of the ELLIPTA inhaler is a trademark of the GSK group of companies.

Trademarks are property of their respective owners.

modal Window

This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
©2020 GSK or licensor.
FVUWCNT200070 November 2020
Produced in USA.

Efficacy vs SYMBICORT TURBUHALER 400/12* (an ICS/LABA)

TRELEGY significantly improved lung function

TRELEGY significantly improved quality of life

TRELEGY: exacerbation rate

Adverse events and additional safety information from the 24-week, non-US FULFIL trial

Efficacy vs SYMBICORT TURBUHALER 400/12^* (an ICS/LABA)